CD274 and cancer: In recent years, the Food and Drug Administration (FDA) has approved four anti-PD-1 monoclonal antibodies (mAbs), namely pembrolizumab, nivolumab, cemiplimab, and tislelizumab, and three anti-PD-L1 antibodies, namely atezolizumab, avelumab, and durvalumab, for treating several types of cancers [17].